Tis the season for skincare! Don't wait until the last minute to secure your holiday gifts. Get a head start on shopping with ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

An update from Codexis ( (CDXS) ) is now available. Codexis, Inc. has appointed Raymond De Vré as a new Class I director to its Board, ...

First, a little history on Epidermal Growth Factor: in the 1950s, the scientists who discovered EGF, which is a polypeptide or protein that our bodies produce throughout our lives, were awarded the ...

StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical ...

A new guideline released on World Diabetes Day will give GPs and other health professionals positive recommendations for optimal diabetes management ...

They also include a combination of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, or GLP-1/GIP. Many of these GLP-1 and GLP-1/GIP receptor agonists were initially ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...